Comprehensive analysis of SYTL4 differential expression and clinical implications in DLBCL.
- Open access
Elevated SYTL4 expression is linked to poorer prognosis and may serve as a diagnostic, prognostic, and therapeutic biomarker in DLBCL, with a hazard ratio of 25.541.
- Why it matters: DLBCL exhibits heterogeneous clinical outcomes, and identifying reliable biomarkers is crucial for improving risk stratification and personalized treatment options for patients.
- What they did: The study analyzed RNA-seq data from TCGA and GTEx, performed survival and functional analyses, and validated SYTL4 expression through immunohistochemistry in tissue samples from DLBCL patients.
- The result: High SYTL4 levels correlate with unfavorable prognosis and are associated with genes involved in cell adhesion and immune response, suggesting its role in DLBCL progression and potential as a therapeutic target.